Ex-vivo delivery of monoclonal antibody (Rituximab) to treat human donor lungs prior to transplantation

BACKGROUND: Ex-vivo lung perfusion (EVLP) is an innovative platform for assessing donor lungs in the pre-transplant window. In this study, we demonstrate an extension of its utility by administering the anti-CD20 monoclonal antibody, Rituximab, during EVLP. We hypothesized that this would lead to ta...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:EBioMedicine
Päätekijät: Ku, Terrance J.Y., Ribeiro, Rafaela V.P., Ferreira, Victor H., Galasso, Marcos, Keshavjee, Shaf, Kumar, Deepali, Cypel, Marcelo, Humar, Atul
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2020
Aiheet:
Research paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7501077/
https://ncbi.nlm.nih.gov/pubmed/32950000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102994
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia